Autors: Wire Reports, TALLINN Datums: 30.05.2013 Izdevums: The Baltic TimesRubrika: Bussiness
Virexxa, a drug candidate developed at the Estonian Cancer Research Technology Development Center, will be produced by Estonian company Kevelt, in what is of symbolic importance for the Estonian bio-technology industry, reports Public Broadcasting.
Lai lasītu visu rakstu, lūdzu, ienāciet sistēmā